Immunohistochemistry in marginal-zone lymphomas and DLBCL confirmed a B-cell origin, given the strong expression of PAX5 and the lack of CD3 immunoreactivity (Figure 4B,C,E,F). This evidence concerns the gene PAX5 and marginal zone lymphoma.